Skip to main content
    L

    Lixte Biotechnology Holdings Inc (LIXT)

    Official site

    BIOTECHNOLOGY

    $7.21
    -0.46 (-6.00%)

    Last updated: Jul 02, 2026 at 5:00 PM ET

    Lixte Biotechnology Holdings Inc (LIXT) Financials: Revenue, Profit and Cash Flow

    Updated May 14, 2026. Financial statements from company filings, amounts in US dollars.

    Lixte Biotechnology Holdings reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$6.01M, operating cash flow was -$3.07M and free cash flow was -$3.07M. The quarter ended Mar 31, 2026 had revenue of $0 and net income of -$1.92M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $5.11M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Mar 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Research and development$254.92K$726.23K$898.10K$1.35M$1.74M$1.22M$820.91K$40.70K$467.26K$1.30M
    Operating income-$5.11M-$3.57M-$5.09M-$6.31M-$6.72M-$3.27M-$2.49M-$2.14M-$1.81M-$2.13M
    Net income-$6.01M-$3.59M-$5.09M-$6.31M-$6.73M-$3.26M-$2.39M-$2.13M-$1.81M-$2.13M
    EBITDAN/A-$3.57M-$5.07M-$6.30MN/A-$3.26M-$2.49M-$2.13M-$1.81M-$2.13M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Operating income-$1.99M-$1.82M-$1.80M-$774.81K-$706.94K-$613.50K-$983.26K-$1.01M-$966.88K-$1.03M-$1.02M-$1.67M
    Net income-$1.92M-$2.54M-$2.03M-$775.67K-$709.55K-$617.69K-$986.03K-$1.01M-$971.32K-$1.03M-$1.02M-$1.67M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $664.49K by $4.44M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$12.73M$1.15M$4.31M$5.56M$5.09M$5.23M$2.67M$4.34M$1.37M$433.41K
    Current assets$5.18M$1.04M$4.23M$5.56M$5.09M$5.23M$2.67M$4.33M$1.37M$433.41K
    Cash and equivalents$5.11M$1.04M$4.20M$5.35M$4.82M$5.07M$2.60M$4.27M$1.31M$199.93K
    Total liabilities$1.77M$318.28K$313.86K$394.79K$302.93K$216.52K$237.90K$210.91K$373.02K$218.65K
    Short-term debt$664.49KN/A$313.86K$394.79K$302.93KN/A$237.90K$210.91K$60.99K$59.06K
    Shareholder equity$9.66M$827.22K$3.99M$5.17M$4.79M$5.01M$2.43M$4.13M$995.04K$214.76K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total assets$10.87M$12.73M$5.43M$1.19M$1.51M$1.15M$1.70M$2.67M$3.59M$4.31M$5.23M$3.10M
    Total liabilities$1.69M$1.77M$521.42K$537.12K$355.10K$318.28K$328.96K$421.46K$462.84K$313.86K$311.74K$402.61K
    Cash and equivalents$3.25M$5.11M$2.89M$887.21K$1.38M$1.04M$1.64M$2.60M$3.41M$4.20M$5.11M$2.91M
    Shareholder equity$7.95M$9.66M$4.91M$651.46K$1.16M$827.22K$1.37M$2.25M$3.13M$3.99M$4.92M$2.69M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$3.07M-$3.16M-$4.29M-$4.61M-$4.14M-$2.13M-$1.67M-$1.51M-$1.41M-$1.68M
    Capital expenditures$0$4$5$3$5$4$0$0$0$0
    Free cash flow-$3.07M-$3.16M-$4.29M-$4.61M-$4.14M-$2.13M-$1.67M-$1.51M-$1.41M-$1.68M
    Dividends paid$69.07MN/AN/AN/AN/AN/AN/AN/AN/A$2.00K
    Investing cash flow-$3.17MN/AN/A$5.14MN/AN/AN/AN/AN/A$104.09K
    Financing cash flow$10.31M$0$3.14M$5.14M$3.90M$4.60M$4.60M$4.48M$2.52M$1.75M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Operating cash flow-$1.83M-$1.09M-$926.75K-$487.49K-$568.48K-$598.67K-$957.60K-$819.04K-$789.23K-$902.12K-$944.39K-$1.18M
    Capital expenditures$24.86K$3$2$5$3$0$5$0$0$3$0$4
    Free cash flow-$1.86M-$1.09M-$926.75K-$487.49K-$568.49K-$598.67K-$957.60K-$819.04K-$789.23K-$902.13K-$944.39K-$1.18M
    Last 12 quarters

    Frequently Asked Questions About LIXT

    What is Lixte Biotechnology Holdings' annual revenue?

    Lixte Biotechnology Holdings reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Lixte Biotechnology Holdings profitable?

    No. Lixte Biotechnology Holdings reported net income of -$6.01M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does LIXT generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$3.07M minus capital expenditures of $0 produced free cash flow of -$3.07M.

    How much debt does Lixte Biotechnology Holdings have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $664.49K and cash and equivalents of $5.11M.